Autonomix Medical, Inc. (NASDAQ: AMIX)

Autonomix Medical, Inc. is a development stage medical device company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first in class technology platform includes a catheter based microchip enabled sensing array that can detect and differentiate neural signals with high sensitivity as demonstrated in animal studies. The company is initially targeting pancreatic cancer pain but believes its platform can address chronic pain hypertension cardiovascular disease and a wide range of other nerve related disorders. Development efforts are organized into two main areas diagnostic sensing and therapeutic radiofrequency ablation. Diagnostic sensing aims to identify disorder related neuronal activity with enough precision to enable targeted therapy while therapeutic radiofrequency ablation focuses on delivering energy to ablate problematic nerves. The firm has completed a first in human proof of concept trial that evaluated the safety and effectiveness of delivering transvascular energy to ablate nerves in pancreatic cancer patients and is now advancing to a follow on proof of concept phase that expands to additional visceral cancers. All work remains preclinical or early clinical and the device has not yet received regulatory clearance for commercial sale.

We currently generate no product revenue as we remain in the development stage. Our anticipated revenue model centers on the sale of single use disposable catheters that include a sensing component and an ablation component to hospitals and interventional radiology suites. Revenue will be tied to the number of procedures performed using our system. We also expect to offer the radio frequency energy source and associated software either as part of the catheter kit or as separate accessories. In addition we anticipate that the software component will be provided at low or no cost to reduce barriers for adoption. Over time we may generate revenue from licensing arrangements or partnerships with larger medical technology firms that seek to incorporate our nerve sensing technology into their own product lines.

The company does not report separate operating segments in its current filings.

Within the electrophysiology and neuromodulation markets Autonomix Medical, Inc. positions itself as a pioneer of high sensitivity nerve signal detection. Its main competitors include large established firms such as Medtronic and Boston Scientific which dominate traditional cardiac ablation and sensing markets. The company's competitive advantage lies in its proprietary microchip that processes signals immediately at the electrode site enabling detection of microvolt level nerve activity that existing systems miss. This capability allows for targeted ablation and reduces the risk of off target effects compared with blind procedures. By focusing on the peripheral nervous system rather than solely the heart the firm aims to expand the addressable market beyond current electrophysiology estimates. According to industry reports the global electrophysiology market generated approximately $6.8 billion in 2021 and is projected to reach $11.6 billion by 2027. The broader pain management market is estimated at $75 billion while the hypertension treatment market is valued at about $23 billion. Autonomix believes its platform can address a portion of these large markets by providing a tool that works across the peripheral nervous system for conditions ranging from chronic pain to cardiovascular disease.

The company intends to serve hospitals interventional radiology labs electrophysiology suites cardiology and gastroenterology departments that perform procedures involving nerve sensing and ablation. In addition pain management clinics and outpatient centers that treat chronic pain may become users of the technology. While no specific customer names have been disclosed the expected users are medical institutions seeking innovative tools for pain management hypertension treatment and other nerve related conditions. The firm also anticipates that academic research hospitals and specialty centers focused on neurovascular interventions could adopt the system for clinical trials and early adoption programs.